Contraindicated (1)bortezomib will improve the stage or influence of mavacamten by influencing hepatic enzyme CYP2C19 metabolism. Contraindicated. Powerful or reasonable CYP2C19 inhibitors may well maximize mavacamten systemic publicity, resulting in heart failure on account of systolic dysfunction. Unlock 38% more drug discovery time and get rid of determination-making uncertainties ... https://gregorybwohy.oblogation.com/26533593/fascination-about-2